<DOC>
	<DOCNO>NCT01579383</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics ALD403 , monoclonal antibody , administer intravenous infusion subcutaneous injection .</brief_summary>
	<brief_title>Safety Tolerability Pharmacokinetics ALD403</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Inclusion Criteria Part A : Healthy male female age 18 65 ( inclusive ) . Normal renal function calculate Cockcroft Gault equation screen . Body Mass Index ( BMI ) 18.0 30.0 kg/m2 , total body weight 50 100kg inclusive . No clinically significant disease abnormal laboratory value determine medical history , physical examination , electrocardiogram , laboratory evaluation Exclusion Criteria Part A : History febrile illness within 5 day prior first dose Any clinically significant laboratory finding Any clinically significant physical exam abnormality Hospitalization reason within 30 day screen visit . History positive human immunodeficiency virus ( HIV ) screen result History positive Hepatitis B surface antigen ( HBsAg ) , and/or positive Hepatitis C antibody ( HCV ) screening . History malignancy within five year prior screen . History leukemia , myeloproliferative disorder lymphoproliferative disorder History rubber , latex allergy allergy medical adhesive Positive urine , drug alcohol screen result Current smoker Previous treatment clinical trial monoclonal antibody . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives Inclusion Criteria Part B : Healthy female age 18 65 ( inclusive ) . Male female migraine patient clinically diagnose migraine attribute another cause without aura base International Headache Society criterion . Migraine patient must history migraine without aura 1 year 18 moderate severe migraine attack per month 2 month prior start study . Normal renal function define Cockcroft Gault equation screen . Body Mass Index ( BMI ) 18.0 30.0 kg/m2 , total body weight 50 100kg inclusive . No clinically significant disease abnormal laboratory value determine medical history , physical examination , electrocardiogram , laboratory evaluation conduct screen visit time admission Exclusion Criteria Part B : For migraine patient : patient able refrain use usual triptan therapy ( applicable ) 48 hour ( Day 2 ) prior dose Day 1 morning discharge ( Day 3 ) . Migraine patient experience migraine prolong aura , familiar hemiplegic migraine , migrainous infarction basilar migraine For migraine patient : patient 8 headachedays per month take medication acute headache 8 day month past 3 month For migraine patient : patient great 50 year old age migraine onset History febrile illness within 5 day prior first dose Any clinically significant laboratory finding Any clinically significant physical exam abnormality Previous treatment clinical trial monoclonal antibody . Hospitalization reason within 30 day screen visit . History positive human immunodeficiency virus ( HIV ) screen result History positive Hepatitis B surface antigen ( HBsAg ) , and/or positive Hepatitis C antibody ( HCV History malignancy within five year prior screen . History leukemia , myeloproliferative disorder lymphoproliferative disorder Positive urine drug alcohol screen result Current smoker . Known contraindication sumatriptan Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Migraine Disorders</keyword>
	<keyword>Phase 1</keyword>
	<keyword>ALD403</keyword>
</DOC>